Loss of ferrochelatase is protective against colon cancer cells: ferrochelatase a possible regulator of the long noncoding RNA H19 | Zendy

Rémi Safi | Zendy; Tala MohsenKanson | Zendy; Georges Nemer | Zendy; Batoul Dekmak | Zendy; Nelly Rubeiz | Zendy; Marwan El Sabban | Zendy; Dany Nassar | Zendy; Assaad A. Eid | Zendy; Ossama Abbas | Zendy; AbdulGhani Kibbi | Zendy; Mazen Kurban | Zendy

Open Access

Loss of ferrochelatase is protective against colon cancer cells: ferrochelatase a possible regulator of the long noncoding RNA H19

Author(s) -

Rémi Safi,

Tala MohsenKanson,

Georges Nemer,

Batoul Dekmak,

Nelly Rubeiz,

Marwan El Sabban,

Dany Nassar,

Assaad A. Eid,

Ossama Abbas,

AbdulGhani Kibbi,

Mazen Kurban

Publication year - 2019

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2019.03.09

Subject(s) - ferrochelatase , carcinogenesis , cancer research , colorectal cancer , downregulation and upregulation , cancer , gene knockdown , cancer cell , gene silencing , biology , medicine , cell culture , gene , heme , enzyme , genetics , biochemistry

Ferrochelatase (FECH) is the last enzyme of the heme biosynthesis pathway. Deficiency in FECH was associated with many diseases, including protoporphyria. Correlation studies showed that variations of FECH expression was detected in human carcinomas and more specifically in colon cancer. Nevertheless, the potential role of FECH in colon cancer carcinogenesis in vitro was not depicted yet.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research